Provepharm Articles
Novartis gains positive CHMP opinion for Rasilamlo, as do CSL Behring for Hizentra and Provepharm for Proveblue
21 February 2011
Showing 1-2 of 2 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
